Skip to content


Qelbree (viloxazine) is a small molecule pharmaceutical. Viloxazine was first approved as Qelbree on 2021-04-02. It is used to treat depression in the USA. Qelbree's patent is valid until 2033-02-07 (FDA).
Trade Name Qelbree
Common Name Viloxazine
Indication depression
Drug Class Antidepressant; Norepinephrine reuptake inhibitor
Get full access now